SRR4296110
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.590
- INFLAMMATORY_RESPONSE+0.480
- UV_RESPONSE_DN+0.430
- IL6_JAK_STAT3_SIGNALING+0.410
- TGF_BETA_SIGNALING+0.400
- IL2_STAT5_SIGNALING+0.380
- COMPLEMENT+0.330
- APOPTOSIS+0.320
- INTERFERON_GAMMA_RESPONSE+0.290
- CHOLESTEROL_HOMEOSTASIS+0.280
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- GLYCOLYSIS-0.370
- MYC_TARGETS_V1-0.330
- E2F_TARGETS-0.320
- DNA_REPAIR-0.230
- OXIDATIVE_PHOSPHORYLATION-0.220
- PEROXISOME-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- G2M_CHECKPOINT-0.190
- PANCREAS_BETA_CELLS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.870 |
| 2 | TCGA-A8-A0A1-01A-11R-A00Z-07 | — | A | 0.865 |
| 3 | MNG572 | — | — | 0.864 |
| 4 | SAMN03290930 | — | — | 0.847 |
| 5 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.844 |
| 6 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.842 |
| 7 | SRR23303755 | — | — | 0.841 |
| 8 | SRR934720 | — | — | 0.840 |
| 9 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.836 |
| 10 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.590 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |